Xtandi Reduces Risk of Metastasis in Castration-resistant Prostate Cancer, Phase 3 Trial Shows

Xtandi Reduces Risk of Metastasis in Castration-resistant Prostate Cancer, Phase 3 Trial Shows
Treatment with Xtandi (enzalutamide) reduced the risk of metastasis or death in castration-resistant prostate cancer (CRPC) patients whose cancer has not yet spread beyond the prostate, Pfizer and Japan-based Astellas Pharma recently announced. The Phase 3 PROSPER trial evaluated whether adding Xtandi to the standard androgen deprivation therapy (ADT) was better than ADT alone in patients whose

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *